The arrival of summer has intensified body image anxieties, reigniting a fervor for "slimming injections." Fueled by a deluge of promotional content on social media, GLP-1 drugs are rapidly replacing diet and exercise as the popular shortcut to "effortless weight loss."
As prescription medications clinically approved for treating type 2 diabetes, GLP-1 formulations originally had strict medical boundaries for use. However, propelled by widespread appearance anxiety, their disease-treating properties have gradually diminished while their cosmetic and weight-loss attributes have been amplified to an extreme. From office workers to university students, from middle-aged obese individuals to those seeking body contouring, diverse groups have joined the fray, continuously heating up this trillion-dollar weight management sector: pharmaceutical companies are racing to launch products, aesthetic medicine channels are stocking up, online consultations are surging, and gray market chains are proliferating. A complex industry game, entangled with expansion benefits, public misconceptions, and blurred regulatory lines, is quietly unfolding.
The Surge of Participants: An Old Diabetes Drug Taps a Trillion-Dollar Market
Xiao Bai, 28, who has worked in Shanghai for years, once grappled with a health crisis stemming from obesity. Six months ago, weighing 196 pounds and diagnosed with fatty liver combined with sleep apnea, he was warned by doctors about chronic disease risks, leading to his first encounter with GLP-1 receptor agonists.
After a full endocrinology screening and evaluation, Xiao Bai was approved for prescription use. "One injection a week, and afterward, I barely feel like eating." Under standardized clinical drug intervention, his weight was effectively controlled, and various high-risk indicators for chronic diseases gradually improved. The visible weight management results prompted five or six relatives and friends around him to follow suit.
Xiao Bai's experience epitomizes the explosive growth of the GLP-1 weight management field in recent years. In 2021, Novo Nordisk's semaglutide was approved for weight loss in the United States, officially igniting the global market. Leveraging its first-mover advantage, Novo Nordisk captured the first wave of benefits in the Chinese market. Financial reports show that in 2025, sales of its semaglutide weight-loss version in China surged over 314% year-on-year, far exceeding the growth rate of traditional drug pipelines. Following closely, Eli Lilly, relying on the dual-target technological advantage of tirzepatide and its more pronounced weight-loss effects, launched a strong counteroffensive, with quarterly sales surpassing its rival at one point in 2025.
Domestic innovative pharmaceutical companies are also accelerating their breakthroughs. In June 2025, Innovent Biologics' globally first-in-class GLP-1/GCG dual-target drug, mazdutide, was approved for weight loss, quickly capturing about 12% of the market share with its flexible channel strategy and localization advantages.
The true patent cliff arrived this year. The core compound patent for semaglutide officially expired on March 20 in China and India, two major generic drug markets. Currently, at least ten companies have submitted applications for marketing approval of semaglutide biosimilars, with GeneScience Pharma's application for the weight-loss indication receiving official acceptance this February. However, constrained by the data protection rules of the China-Switzerland Free Trade Agreement, semaglutide's data protection period extends until April 2027, meaning the commercialization of the first domestic generics still requires time. This explains the aggressive strategies of multinational pharmaceutical companies: to seize the final exclusive benefits within the remaining patent window by lowering prices to boost volume, expanding into lower-tier markets, conducting academic promotions, and raising public awareness.
Industry Race to Capture Benefits
With the dense approval of new products, industry competition has intensified, with multinational pharmaceutical firms initiating a price war. Novo Nordisk significantly reduced the pricing of its core products, lowering the regular-dose diabetes version of semaglutide (Ozempic) to 660 yuan per pen, while the high-dose weight-loss version (Wegovy) plummeted from nearly 1900 yuan to 987 yuan. Eli Lilly's tirzepatide was available for as low as around 450 yuan per pen on e-commerce channels. The ongoing price reshuffling is rapidly pushing the GLP-1 sector from a "high-premium profit period" into a "scale competition period."
Beyond the price war, full-channel expansion has become a common growth strategy for companies. Online channels are at the forefront. Compared to the strict prescription approval processes in public hospitals, online drug sales channels have significantly lowered entry barriers. Since liraglutide was approved for weight loss, various GLP-1 drugs quickly entered major e-commerce platforms. The online consultation process is highly simplified; users only need to check symptoms and confirm past medication history to quickly obtain an electronic prescription with cold-chain delivery to their doorstep. Platforms cannot verify users' actual weight, medical records, or medication suitability, and terminal pharmacies also lack the authority or responsibility for verification. This lax online review allows a large number of consumers without proper medical indications to easily purchase the drugs.
It is essential to clearly distinguish three usage scenarios; the following chaos does not fall within the scope of compliant clinical treatment: first, compliant prescription weight-loss medication following strict indication approval by medical institutions; second, off-label use by healthy individuals seeking body shaping without medical indications; third, unregulated counterfeit drugs circulating in channels and smuggled prohibited drugs from overseas.
In the eyes of channel agents, the oral version of semaglutide, which has not yet been approved for weight loss domestically, is currently the "biggest cake" in the GLP-1 sector. Currently, this drug is only approved for diabetes treatment, with weight-loss application being a typical case of off-label use. Pursuing convenience, many consumers bypass regulations by purchasing the drug without prescriptions through direct mail channels from pharmacies in places like Hong Kong. However, some users report that versions circulating from Japan, Bangladesh, and other regions have inconsistent efficacy and are difficult to authenticate.
Market data confirms the shift in channel dynamics. In the fourth quarter of 2025, the scale of GLP-1 drug sales via e-commerce channels reached 1.8 billion yuan, while hospital channel sales were 2.1 billion yuan. The gap between online and offline market sizes is narrowing rapidly, indicating a clear trend towards channel decentralization. Notably, 82% of online drug purchasers cite weight loss and body shape management as their core motivation, signaling the rapid transformation of weight-loss drugs into mass-market cosmetic and body-shaping consumer products.
Simultaneously, social media platforms are also fueling the "aesthetic medicalization" of GLP-1. Algorithms precisely target appearance anxieties, and viral content continuously amplifies the fantasy of rapid fat loss aided by drugs, turning what was originally a prescription drug strictly for use in hospital endocrinology departments into an internet sensation hailed as a "slimming magic weapon." Posting injection processes, sharing body management before-and-after photos, and discussing medication experiences have become a new form of social currency, with leading drugs turning into网红 symbols. What should be a private, rigorous medical act is gradually evolving into a public performance for gaining traffic and following trends, paving the way for continued drug abuse and off-label consumption.
In this "aesthetic medicalization" process, most leading pharmaceutical companies generally adhere to compliance red lines and explicitly oppose drug abuse. However, some downstream distribution channels and third-party marketing agents continuously amplify the "slimming and beautifying" consumer scenario for indirect traffic generation, operating on the fringes of industry compliance. In fact, a significant portion of GLP-1 drug sales comes from off-label use, i.e., consumption by healthy individuals without medical indications seeking body shaping. While most pharmaceutical companies publicly promote strict compliance and oppose abuse, the marketing end struggles to control downstream channels' indirect promotional tactics that downplay the drug's medical attributes, exaggerate its aesthetic value, and help push prescription drugs across the boundary to become网红 consumer products.
A plethora of self-injection tutorial videos has further lowered the barrier to use while amplifying safety risks. Most ordinary consumers learn to self-inject solely through fragmented online tutorials, completely disregarding sterile operation standards, principles of individualized dosage adaptation, and medication contraindications.
The Myth of "Effortless Slimming" and Its Hidden Costs
The "aesthetic medicalization" has lowered the barrier to drug use, but the health costs paid by consumers are selectively ignored. Beneath the滤镜 of "painless effortless slimming" lie downplayed health risks and bodily strain. Gastrointestinal adverse reactions are the most typical and common short-term side effects of GLP-1 drugs. Public clinical data shows that over half of users experience nausea, about 30% suffer from diarrhea, constipation, vomiting, and other discomforts, with gastroesophageal reflux also being highly prevalent. These reactions typically occur during the initial medication phase, with only some users gradually adapting and tolerating them over extended use.
More concerning are the medium- to long-term risks. Severe chronic conditions like gastroparesis, persistent gastrointestinal motility disorders, and irritable bowel syndrome observed clinically mostly occur in individuals who abuse the drug without professional medical advice,私自 increasing doses, or using it blindly long-term. These are secondary health risks arising from improper use, not常规 clinical adverse reactions of the drug. Side effects like dizziness, headaches, and hypoglycemia are also common issues requiring close monitoring during standard clinical use.
Furthermore, the "one-shot slimming" trend is not only reshaping individual body management approaches but also quietly altering the competitive landscape of the broader health industry. The powerful siphoning effect of GLP-1 drugs has left traditional weight-loss sectors collectively facing a downturn and accelerating contraction. Once-popular mass-market weight-loss categories like meal replacement powders, slimming teas, and enzymes have seen a sharp decline in热度, with网红 brands exiting rapidly. Gym attendance and annual membership sales have significantly dropped, as time-consuming and strenuous exercise-based fat loss is gradually being replaced by drug-induced slimming. The aesthetic medicine industry is proactively transforming, scaling back traditional liposuction surgeries with significant trauma and long recovery periods, and positioning GLP-1 weight-loss injections as a core profit driver for their slimming divisions.
Industry data直观 reflects this冷暖 differentiation. From August 2024 to August 2025, sales of offline meal replacements and weight-loss nutritional products in the U.S. fell by 3% year-on-year, while sales on Amazon's online channel plummeted by 14%. In stark contrast, GLP-1 related products achieved全渠道 growth as high as 35%. Even the traditional OTC weight-loss drug orlistat, leveraging its non-invasive, injection-free advantage to cater to conservative weight-loss seekers, achieved rapid growth of 42%.
From Chaos to Order: Correcting the "Aesthetic Medicalization" of Drugs
Amid the sector's狂飙, gray market chains have grown unchecked. Due to its market-recognized stronger weight-loss effect, tirzepatide commands a premium in unofficial channels. According to observations by Mr. Wang, head of a康养 institution, many around him purchase the drug through irregular channels, with more隐秘 paths circulating within client groups—"commissioning diabetic patients to make purchases or having them use special outpatient services for reimbursement."
Driven by huge profits, counterfeiting methods are constantly升级, with illegal "网红 weight-loss injections" operating完全脱离监管. A batch of unregulated products like "Transport Protein" and "Slimming King," marketed with slogans like "no dieting needed, one shot to get slim," are packaged as网红爆款, attracting大量 consumers. Some users have experienced severe health damage after injection. More alarmingly,不法分子 smuggle foreign clinical trial drugs that have not passed safety verification into the country, with完全不可控 risks.
Fortunately, regulatory rules are accelerating their落地. On May 15, 2026, the new "Regulations for the Implementation of the Drug Administration Law" officially took effect. Drug regulatory departments across the country simultaneously tightened controls on GLP-1 drug circulation, clearly delineating red lines: retail drug enterprises must sell prescription drugs based on prescriptions, strictly prohibiting违规操作 like "selling first, supplementing the prescription later." Shanghai, Jiangxi, and other regions further require that injectable GLP-1 drugs must be purchased with a paper hospital prescription valid for three days, no longer accepting electronic prescriptions from internet hospitals.
The implementation of these new regulations directly终结 the industry潜规则 of recent years where "e-commerce was the channel, traffic was the prescription." It returns处方 decision-making power from the流量 market back to the medical professional system,打破 the原本畸形的利益分配格局, and presses the "standardization button" for the狂热 GLP-1 market.
Capital chases trends and profits, the market peddles焦虑, and the public craves shortcuts.纵观 this trillion-dollar sector's狂欢, the root of all chaos lies in the divergence between商业 logic and medical logic. Capital pursues traffic, repeat purchases,暴利, and规模化 expansion, packaging prescription drugs as fast-moving consumer goods for全民. Medicine坚守 indications, monitoring, follow-up, and精准施治, serving only patients with genuine刚需. One side seeks a market scale of "the more users, the better"; the other guards the医疗 boundary of "only those who need it should use it." These two conflicting paths have created the industry's狂热 and失序.
The wind has risen in the trillion-dollar赛道, but the喧嚣 must ultimately归序. The trillion-dollar market of the GLP-1 weight-loss sector is not虚火. The诊疗需求 for obesity as a chronic metabolic disease真实存在. Compliant diabetes medication under医保 coverage and medical intervention for severely obese patients are正规医疗服务 with social value. However, for the野蛮生长的 weight-loss market, regulation needs to tighten the reins,肃清 gray circulation chains,规范 off-label abuse, and补齐用药安全短板, allowing prescription drugs to回归 their医疗本源.
It must be clarified that GLP-1 formulations are正规临床慢病治疗药品 approved by national drug regulatory authorities, with their用药安全保障 by规范体系保障. The various market乱象 are本质上 problems of drug abuse caused by失范流通渠道, consumer shortcut mentality, and叠加 appearance anxiety, not inherent safety defects in the drugs themselves. As for every individual, it is crucial to破除容貌焦虑 and摒弃捷径执念. True health is not about讳疾忌医, nor is it速成减脂 brought by药剂. It is about敬畏医学 and掌控规律生活.